Drugs / GSK3358699
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03426995 | Mar 2018 → May 2019 | rheumatoid arthritis | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3358699 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03426995 ↗ |
| Action | Inhibit | “GSK3358699 is a mononuclear myeloid-targeted bromodomain and extra-terminal domain (BET) family inhibitor which demonstrates immunomodulatory effects in vitro.” PMID 34773923 ↗ Dec 2021 |